The company has $400 million, enough cash to potentially build off results from an early-stage leukemia yet this quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback